12:00 AM
 | 
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EPI-A0001: Phase I data

In a placebo-controlled Phase I trial in healthy volunteers, A0001 produced no drug-related serious adverse events. Penwest received exclusive rights to A0001...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >